Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia We enrolled 16 patients ...

Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Jazz Pharmaceuticals announced that adding lurbinectedin ...

More information: Jonathan Weitz et al, Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations, Journal of Clinical Oncology (2024).

CDK4/6 inhibitor palbociclib (Ibrance) may be effective for patients with peritoneal mucinous carcinomatosis characterized by GNAS mutations, a small study indicated. (Journal of Clinical Oncology ...

It can help identify infections, inflammation, or cancer cells. Cancer cells can appear in the cerebrospinal fluid (CSF) if you have carcinomatosis—a condition in which multiple areas of one organ are ...

The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...

Generalised eruptive keratoacanthoma of Grzybowski (GEKA) is a rare disease characterised by the sudden appearance of ...

A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, ...

stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis (PMC). This form of cancer originates in the appendix and is often resistant to ...